
Commercialization
Latest News
Latest Videos

Shorts

Podcasts
More News

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.

FDA’s final guidance on prescription drug use-related software clarifies when companion app content is labeling, promotion or belongs in the PI.

As HCPs turn to AI tools for clinical answers, pharma brands must optimize for share of answer over share of voice and speed up data operations.

In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.

Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.

The earliest development decisions shape everything that follows, from launch timelines and investor confidence to long-term market success.

The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.

Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.

As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.

Virtual care's pre- and postvisit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after FDA approval.

EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.

Across pricing, supply chain, and patient support, the playbooks of pharma commercialization are being rewritten at once for a new era.

















